Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Darzalex (daratumumab) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) Disease area(s): Oncology/hematology Manufacturer(s): Johnson & Johnson 2024 Sales (USD): $11.67 billion Why it sold so well: Anti-CD38 monoclonal antibody Darzalex and its subcutaneous formulation, Darzalex Faspro, had exceptional success in 2024, becoming J&Js top-selling pharmaceutical product with global net sales of $11.67 billion a 19.8% increase over 2023
TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity
Manufacturer specifications for BD Ultrafine and standard insulin syringe product lines, including dead space data and gauge comparisons
The practical advantages of topical: easy to apply, local delivery, lower systemic exposure, and you don't need a needle
Administering doses at bedtime rather than during the day can help manage this effect
